ArticleThe American journal of tropical medicine and hygiene2025
Successful Use of Fludrocortisone for the Management of Trimethoprim-Sulfamethoxazole-Induced Hyperkalemia: A Case Series.
Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 1-Minute Pearls/Pitfalls for the Clinician.Journal of Brown hospital medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trimethoprim-sulfamethoxazole (TMP-SMX) is a widely used antibiotic for various infections but is often associated with hyperkalemia. In this case series, we evaluate the use of fludrocortisone (FCS), a mineralocorticoid receptor agonist, in managing TMP-SMX-induced hyperkalemia. Six patients treated with TMP-SMX for infectious indications developed hyperkalemia within 2-6 days of therapy initiation. The administration of FCS at doses ranging from 0.1 to 0.2 mg daily effectively stabilized potassium levels in all patients within 1-2 days, allowing most to continue the TMP-SMX treatment. These findings highlight the efficacy of FCS in mitigating TMP-SMX-induced potassium retention, thereby providing a safe and practical approach to maintaining essential antibiotic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.